Congrats to our co-founder & CPO Lex Johnson on being named to @BioSpace's 40 Under 40 list! Lex has been instrumental in building Dispatch from the ground up, and we wouldn’t be where we are today without his scientific vision and dedication. Details: biospace.com/lex-johnson

At Dispatch, we’re advancing a first-of-its-kind pipeline of novel immunotherapy programs for solid tumors. Our Flare platform tags tumor cells with a universal antigen, activating the immune system and remodeling the microenvironment. Learn more: dispatchbio.com/pipeline/

Solid tumors have been challenging to treat with immunotherapy due to limitations that DISP-10 is designed to overcome. DV-10 aims to mark tumor cells for CAR T, then replicate to infect cancer cells, creating a feedback loop designed to work across all solid tumor types.

Today, we announced the first patient has been dosed in the Ph1 trial of DISP-10, which has received Fast Track designation from the U.S. FDA. DISP-10 is a novel, investigational therapy designed to address key challenges in treating solid tumors. dispatchbio.com/news/first-p…

GI cancers remain among the toughest to treat, with limited options beyond chemo for advanced disease. DISP-10 combines DV-10, a tumor-specific virus, with a BCMA-directed CAR T therapy, for a new #immunotherapy approach.

Our co-founder & CPO phoned into @LifeSciencesPA’s podcast: Being a Life Sciences Leader. The conversation covers our story , approach to immunotherapy, what it means to be named Emerging Company of the Year by LSPA & more. Dial in: lifesciencespa.org/being-a-l…

Watch the Flare platform in action. A tumor-specific virus tags cancer cells with a Flare antigen ➡️ the immune system follows the beacon to find and clear them while sparing healthy tissue.

~90% of cancers are solid tumors, yet two challenges have long limited immunotherapy here: no tumor-specific targets + a suppressive microenvironment. Our Flare platform was built to solve both. See how it works below.

June is #CancerImmunotherapyMonth. Solid tumors represent ~90% of cancers worldwide, yet tumor microenvironments that suppress immune activity & a lack of tumor-specific targets have historically limited the effectiveness of immunotherapy. We’re working to overcome this.

Our Co-Founder & CPO will join the Frontiers in Cancer Immunotherapy conference, presenting on how synthetic antigen strategies may enable universal immunotherapies across solid tumors. Looking forward to engaging with the IO community. Register here: events.nyas.org/cancerio26